avsv
neg
sens
singlestrand
rna
viru
belong
famili
rhabdovirida
genu
vesiculoviru
wide
explor
vaccin
develop
infecti
diseas
cancer
oncolyt
virusbvsv
caus
selflimit
diseas
hors
pig
cattl
may
either
asymptomat
caus
mild
flulik
syndrom
human
thu
natur
attenu
vector
backbon
develop
human
vaccin
therapiescoth
advantag
vsv
vector
includ
low
preval
immun
vector
popul
target
immun
ii
viral
rna
integr
host
pose
littl
risk
oncogenesi
mutagenesi
iii
larg
foreign
transgen
packag
express
iv
viru
may
pseudotyp
heterolog
viral
glycoprotein
present
envelop
natur
conformationdther
two
major
vsv
serotyp
vsvindiana
vsvnew
jersey
vsvindiana
vsvi
basi
current
vaccin
candid
relat
vesiculovirus
isfahan
viru
maraba
viru
distantli
relat
rhabdovirus
rabi
viru
also
explor
viral
vector
eth
vsv
genom
consist
nucleotid
encod
five
major
protein
vsv
glycoprotein
g
locat
viral
envelop
respons
attach
cell
fusion
endosom
membran
low
ph
releas
viral
genom
rna
cytoplasm
g
protein
also
elicit
protect
immun
vsvfuse
revers
genet
system
vsv
vector
construct
express
gene
diverg
speci
includ
mani
virus
eg
ebola
viru
marburg
viru
lassa
fever
viru
hiv
influenza
viru
hpv
other
see
templat
bacteria
tumor
antigen
construct
portion
vsv
g
protein
retain
facilit
express
enabl
fusion
intern
recombin
viru
vsv
vector
complet
lack
vsv
g
gene
must
reconstitut
attach
fusion
bud
releas
function
one
protein
encod
heterolog
envelop
gene
case
exampl
vsv
g
replac
influenza
hemagglutinin
ha
neuraminidas
na
viru
express
ha
na
vector
produc
replicationcompet
pseudotyp
viru
sinc
protein
play
role
attach
na
need
viru
releas
host
cell
similarli
case
henipaviru
nipah
pseudotyp
express
nipah
glycoprotein
g
respons
cell
attach
produc
replic
viru
unless
fusion
protein
f
protein
nipah
glycoprotein
gp
ebola
zair
coexpress
greplic
pseudotyp
glycoprotein
gp
deriv
mani
differ
filovirus
ebola
zair
ebola
sudan
ebola
reston
marburg
bundibugyo
tai
forest
lloviu
construct
gp
provid
viru
attach
class
fusion
function
advanc
vaccin
candid
describ
templat
express
zair
ebola
viru
zebov
gp
place
vsvi
g
proteinhth
revers
genet
system
produc
involv
cotransfect
cell
plasmid
contain
entir
vsv
genom
g
delet
replac
zebov
gp
togeth
helper
plasmid
express
vsv
n
p
l
gene
transcript
plasmid
control
bacteriophag
polymeras
suppli
babi
hamster
kidney
cell
express
done
exogen
recombin
vaccinia
express
polymeraseith
construct
fulllength
gp
anchor
viral
envelop
wherea
nativ
zebov
express
abund
solubl
form
gp
without
transmembran
domain
solubl
gp
sgp
may
act
decoy
antibodi
contribut
evas
neutral
antibodi
filoviru
infect
gener
sgp
effici
neutral
antibodi
wildtyp
zebov
jthe
full
length
heterolog
gp
incorpor
rvsv
particl
retain
typic
bullet
shape
morpholog
viral
envelop
decor
zebov
gp
spike
instead
vsv
g
protein
spike
gp
spike
compos
disulfid
link
subunit
three
subunit
form
propellerlik
trimer
consist
receptor
bind
domain
glycosyl
mucinlik
domain
glycan
cap
glycan
hypothes
shield
epitop
neutral
antibodi
howev
uncertain
sinc
neutral
occur
prior
cleavag
mucinlik
domain
endosom
moreov
mutat
lack
glycan
effici
elicit
neutral
antibodi
mice
kin
standard
em
studi
insert
ebola
gp
rvsv
particl
alter
typic
bulletshap
vesiculoviru
morpholog
howev
structur
zebov
gp
partial
resolv
cryoem
high
resolut
gp
pseudotyp
vsv
elucidatedlth
cell
target
infect
determin
viru
ligandcel
receptor
interact
may
differ
viru
pseudotyp
zebov
gp
compar
natur
vsv
although
may
overlap
tropism
certain
cell
line
suscept
vsv
zebov
jurkat
cell
insect
cell
permit
replic
primari
vivo
zebov
target
cell
thought
endotheli
cell
monocyt
macrophag
myeloid
dendrit
cell
although
also
presum
hold
true
pseudotyp
rvsv
systemat
studi
cell
type
product
infect
vivo
consist
zebov
gpspecif
tropism
limit
number
observ
suggest
endotheli
cell
target
biodistribut
studi
macaqu
show
vaccin
viru
target
lymphoreticular
tissu
merck
co
inc
kenilworth
nj
usa
newlink
genet
corp
unpublish
data
interestingli
studi
swine
unpublish
describ
templat
show
induc
selflimit
clinic
diseas
histopatholog
cell
tropism
similar
induc
wildtyp
vsv
although
pig
also
suscept
zebov
respiratori
rout
pathogenesi
distinct
caus
vsv
thu
swine
pathogenesi
hostviru
pair
appear
match
vector
backbon
rather
donor
heterolog
envelop
possibl
retent
intact
vsv
gene
virul
factor
vsv
recombin
vector
play
role
pathogenesi
swine
observ
provid
fertil
ground
futur
research
mechan
viral
pathogenesismboth
wild
type
zebov
rvsv
pseudotyp
zebov
gp
appear
enter
cell
macropinocytosi
gp
proteindepend
manner
cell
receptor
initi
process
remain
poorli
defin
entri
appear
involv
clathrin
contrast
vsv
g
protein
bind
lowdens
lipoprotein
receptor
enter
via
receptormedi
endocytosi
clathrindepend
pathway
ctype
lectin
eg
dcsign
put
cell
surfac
receptor
zebov
gp
howev
critic
viruscel
receptor
interact
intracellular
import
consider
immun
recognit
endosom
proteolyt
process
initi
cathepsin
proteas
bind
receptor
endosom
membran
predominantli
niemannpick
protein
cleavag
mucinlik
domain
glycan
cap
requir
receptor
bind
occur
low
ph
conform
rearrang
expos
hydrophob
fusion
loop
insert
endosom
membran
follow
intern
viral
rna
neutral
ebola
viru
antibodi
involv
multipl
differ
mechan
includ
block
cathepsinmedi
proteolyt
cleavag
block
bind
niemann
pick
receptor
inhibit
mediat
fusion
nsinc
vsv
g
gene
delet
antivector
immun
minim
factor
primari
immun
sequenti
use
vector
express
differ
heterolog
genesocomplet
delet
vsv
g
protein
replac
heterolog
transgen
result
highli
attenu
phenotyp
remov
vsv
g
princip
virul
factor
critic
attenu
sinc
construct
retain
g
portion
thereof
show
vari
degre
residu
neurovirul
inject
directli
brain
young
mice
pattenu
vaccin
candid
extens
studi
neurovirul
featur
parent
vsv
infect
follow
intracrani
inject
anim
speci
see
templat
tabl
wherea
viru
pathogen
infant
adult
mice
caus
minim
histopatholog
without
clinic
sign
intracrani
inocul
nonhuman
primat
clinic
biochem
pathoanatom
effect
observ
mice
rat
nonhuman
primat
formal
toxicolog
studi
vaccin
administ
im
full
human
dose
see
templat
vaccin
administ
person
phase
expand
access
clinic
trial
shown
favor
safeti
profil
gener
well
toleratedqvsv
pseudotyp
propag
high
titer
mammalian
cell
although
degre
attenu
observ
compar
wildtyp
vsv
vsv
interferonsensit
viru
interferon
defici
cell
vero
cell
particularli
product
vero
cell
wide
use
manufactur
vaccin
includ
multipl
licens
live
attenu
vaccin
eg
polioviru
smallpox
viru
rotaviru
dengu
viru
viru
grow
plaqueform
unitsml
pfuml
vero
cell
without
serum
anim
deriv
compon
viru
clarifi
filtrat
purifi
concentr
straightforward
process
involv
enzym
digest
ultrafiltrationdiafiltr
without
chromatographi
minim
product
loss
manufactur
process
upscal
produc
larg
quantiti
vaccin
undergo
valid
dedic
facilityrmani
live
replic
vaccin
suscept
thermal
instabl
requir
lyophil
long
term
storag
short
develop
time
west
african
ebola
emerg
vaccin
produc
store
unit
dose
contain
frozen
liquid
formul
store
interestingli
vaccin
found
stabl
thaw
held
least
week
featur
facilit
distribut
use
control
outbreakssth
vaccin
extens
test
nonhuman
primat
respect
immunogen
protect
efficaci
see
templat
tabl
publish
literatur
supplement
multipl
addit
studi
larg
aim
determin
immun
correl
protect
may
bridg
human
immun
respons
elicit
vaccin
effort
ongo
one
studi
igm
subclass
antibodi
suggest
play
domin
role
immun
compar
igg
observ
investigatedtinocul
follow
rapid
appear
viremia
activ
innat
immun
respons
includ
nk
cell
believ
least
partial
respons
protect
challeng
given
day
vaccin
shortli
vaccin
ie
post
exposur
vaccin
gpspecif
igg
antibodi
appear
day
vaccin
tend
peak
day
signatur
innat
immun
marker
appear
first
day
vaccin
found
correl
antibodi
level
appear
later
predomin
among
independ
marker
express
nk
cell
day
independ
correl
observ
consist
live
viral
vaccin
yellow
fever
vaccin
show
predict
innat
signatur
shape
adapt
respons
uth
role
neutral
antibodi
protect
elicit
vaccin
remain
uncertain
vaccin
elicit
robust
neutral
antibodi
respons
follow
vaccin
measur
plaqu
reduct
homolog
vaccin
viru
zebov
pseudovirion
assay
neutral
titer
wildtyp
viru
appear
low
repertoir
antibodi
elicit
vaccin
yet
known
clear
neutral
monoclon
antibodi
highli
protect
passiv
immun
certain
monoclon
antibodi
abrog
infect
prevent
illnessdeath
nhp
model
even
given
day
challeng
addit
neutral
nonneutr
antibodi
function
activ
includ
adcc
phagocytosi
probabl
secondari
mediat
moreov
cooper
effect
nonneutr
antibodi
may
enhanc
potenc
neutral
antibodi
vthere
studi
cell
respons
nhp
human
vaccin
howev
vaccin
appear
elicit
robust
cell
respons
nhp
moreov
cell
deplet
studi
vaccin
nhp
indic
cell
play
role
protect
human
broad
cell
activ
observ
day
vaccin
zebov
specif
cytotox
cell
respons
seen
higher
vaccin
dose
pfu
consist
antibodi
predomin
mediat
protectionwa
substanti
experi
accumul
safeti
immunogen
protect
efficaci
human
tabl
remark
effort
carri
coalit
multipl
intern
partner
short
period
time
intern
public
health
emerg
west
africa
logist
problem
solut
encount
one
larg
trial
chronicl
recent
seri
public
j
infect
di
suppl
xkey
aspect
phase
clinic
trial
engag
particip
detail
templat
overal
administ
select
nomin
dose
pfu
vaccin
proven
safe
well
toler
first
day
vaccin
mani
vaccine
experi
acutephas
reaction
fever
headach
myalgia
arthralgia
short
durat
period
associ
lowlevel
viremia
activ
antivir
gene
increas
level
chemokin
cytokin
oligoarthr
rash
appear
second
week
occur
minor
subject
typic
mildmoder
sever
selflimit
vesicular
mucos
lesion
infrequ
arthriti
skin
event
appear
reflect
direct
viral
injuri
inflamm
immunopatholog
basi
new
vaccin
rare
advers
event
may
detect
accumul
larg
safeti
data
base
million
person
immun
ythe
clinic
trial
shown
vaccin
highli
immunogen
across
broad
dose
rang
pfu
subject
develop
igg
bind
antibodi
elisa
use
recombin
gp
antigen
neutral
antibodi
use
sever
differ
method
predominantli
plaqu
reduct
method
pseudotyp
viru
eg
tabl
tabl
lower
level
neutral
antibodi
wildtyp
ebola
observ
possibl
due
competit
sgp
igg
neutral
antibodi
appear
day
peak
day
plateau
thereaft
least
monthszal
studi
human
nhp
use
im
rout
administr
comparison
subcutan
sc
deliveri
simpli
reflect
rapid
pace
develop
vaccineaaefficaci
vaccin
demonstr
larg
ring
vaccin
trial
guinea
contact
ebola
case
contact
contact
random
receiv
singl
inject
pfu
vaccin
immedi
delay
analysi
efficaci
random
ring
compar
vaccin
subject
immedi
arm
subject
ring
elig
subject
consent
day
delay
arm
subject
ring
ten
case
confirm
evd
ring
observ
elig
subject
delay
vaccin
arm
consent
day
case
evd
occur
vaccin
subject
immedi
arm
day
vaccin
calcul
vaccin
efficaci
analysi
ci
p
remark
trial
conduct
tail
end
west
african
epidem
underpin
regulatori
review
toward
licensur
vaccin
well
preapprov
use
control
outbreak
ebola
viru
diseaseaba
summari
clinic
trial
employ
provid
tabl
find
opinion
conclus
assert
contain
consensu
document
individu
member
work
group
necessarili
repres
offici
posit
particip
organ
eg
govern
univers
corpor
constru
repres
agenc
determin
polici
